[1]王梦蕾殷苗苗马婕馨刘妍刘齐超刘会云*.小儿风热清口服液抗菌药理作用研究*[J].现代中医药,2024,(05):095-103.[doi:10.13424/j.cnki.mtcm.2024.05.018]
　WANG MengleiYIN Miaomiao MA Jiexin LIU Yan LIU Qichao LIU Huiyun.Study on the Antibacterial and PharmacologicalEffects of Xiaoer Fengreqing Oral Liquid[J].Modern Traditional Chinese Medicine,2024,(05):095-103.[doi:10.13424/j.cnki.mtcm.2024.05.018]
点击复制

小儿风热清口服液抗菌药理作用研究*()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年05期
页码:
095-103
栏目:
出版日期:
2024-09-20

文章信息/Info

Title:
Study on the Antibacterial and PharmacologicalEffects of Xiaoer Fengreqing Oral Liquid
文章编号:
1672-0571(2024)04-0093-07
作者:
王梦蕾1殷苗苗2马婕馨3刘妍3刘齐超1刘会云2; 3*
1.河北省（邯郸）中药产业技术研究院，河北 邯郸 056000；
2.河北省中药大品种培育技术创新中心，河北 邯郸 056000；
3.邯郸制药股份有限公司，河北 邯郸 056000
Author(s):
WANG Menglei1YIN Miaomiao2 MA Jiexin3 LIU Yan3 LIU Qichao1 LIU Huiyun2
1.Hebei Province (Handan) Traditional Chinese Medicine Industry Technology Research Institute，Hebei Handan056000，China；
2.Hebei Province Traditional Chinese Medicine Variety Cultivation Technology InnovationCenter，Hebei Handan 056000，China；
3.Ha
关键词:
关键词：小儿风热清; 抗菌; ELISA; A549细胞
Keywords:
Key words:Xiao’er Fengreqing; Antibacterial; ELISA; A549 cells
分类号:
R285.5
DOI:
10.13424/j.cnki.mtcm.2024.05.018
文献标志码:
A
摘要:
摘 要：目的 研究小儿风热清合剂（口服液）抗菌药理作用。方法 采用琼脂二倍稀释法测定小儿风热清对呼吸道常见致病菌肺炎克雷伯菌、肺炎链球菌、流感嗜血杆菌、金黄色葡萄球菌、铜绿假单胞菌、大肠杆菌的最低抑菌浓度（minimum inhibitory concentration，MIC）和最低杀菌浓度（minimum bactericidal concentration，MBC）。采用CCK-8法检测小儿风热清对A549细胞抵抗肺炎链球菌感染能力的影响；采用 ELISA 法检测细胞上清液中一氧化氮（nitric oxide，NO）、白细胞介素-1β（Interleukin-1β，IL-1β）的水平。将雄性BALB/c 小鼠按体质量随机分为正常对照组、模型组、阳性对照组及小儿风热清低、中、高剂量（5.4、10.8、21.6 mL·kg-1）组，除正常对照组外，其余各组小鼠利用细菌内毒素脂多糖（lippoplysaccharides，LPS）口咽吸入法构建小鼠急性肺损伤模型，测定各组小鼠肺指数；采用ELISA法检测小鼠血清中白细胞介素-6（interleukin-6，IL-6）、白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（tumor necrosis factor，TNF-α）水平；采用苏木素-伊红（Hematoxylin-Eosin，HE）染色考察肺组织病理变化。结果 MIC实验结果表明小儿风热清对6种供试细菌均具有抑菌作用；MBC实验结果表明，小儿风热清对除金黄色葡萄球菌外的其他5种供试细菌具有杀菌效果。CCK-8结果显示，与正常对照组比较，肺炎链球菌感染后，A549细胞活力显著下降（P＜0.001），与模型组比较，小儿风热清给药组细胞损伤程度得到改善，细胞活力升高（P＜0.0001，0.01，0.05）；与正常对照组比较，肺炎链球菌感染后，细胞上清液中NO水平（P＜0.001）、IL-1β水平（P＜0.001）显著升高；与模型组比较，小儿风热清给药组细胞上清液中NO、IL-1β水平降低。LPS溶液经小鼠口咽后部吸入肺腔后可导致肺部炎性细胞浸润、肺泡出血充血、肺组织实化，其肺损伤病理评价总分与对照组相比具有显著性差异（P＜0.0001）；与模型组相比，小儿风热清高剂量组小鼠肺指数明显降低（P＜0.05）；血清中IL-6、IL-1β、TNF-α水平降低（P＜0.01、005）；与模型组相比，小儿风热清中剂量组小鼠肺损伤病理评分总分显著降低（P＜0.01），另外小儿风热清低、中、高剂量组均可显著改善肺损伤中肺组织实化程度。结论 小儿风热清对6种呼吸道常见致病菌均具有较强抑制作用，且能够显著改善肺炎链球菌感染A549细胞造成的细胞损伤情况，降低LPS诱导急性肺损伤小鼠肺指数，改善LPS所致肺组织病理形态学异常，提示小儿风热清对细菌内毒素所致小鼠肺损伤具有治疗作用，且具有显著抗菌、抗炎能力。
Abstract:
Abstract：Objective To study the antibacterial and pharmacological effects of Xiao’er Fengreqing mixture (oral liquid).Methods The agar dilution method was used to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of Xiao’er Fengreqing mixture against common respiratory pathogens such as Klebsiella pneumoniae，Streptococcus pneumoniae，Haemophilus influenzae，Staphylococcus aureus，Pseudomonas aeruginosa，and Escherichia coli.The CCK-8 method was used to detect the effect of Xiao’er Fengreqing mixture on the resistance of A549 cells to Streptococcus pneumoniae infection；ELISA was used to detect the levels of nitric oxide (NO) and interleukin-1 β (IL-1β) in the cell supernatant.Male BALB/c mice were randomly divided into normal control group，model group，positive control group，and Xiao’er Fengreqing mixture low，medium，and high dose (5.4，10.8，21.6 mL·kg-1) groups according to body weight.Except for the normal control group，the other groups of mice were used to construct a mouse acute lung injury model by oral inhalation of bacterial endotoxin lipopolysaccharides (LPS)，and the lung index of each group of mice was measured；ELISA was used to detect the levels of interleukin-6 (IL-6)，interleukin-1β (IL-1β)，and tumor necrosis factor-α (TNF-α) in mouse serum；Hematoxylin Eosin (HE) staining was used to investigate the pathological changes in lung tissue.Results The MIC experiment results showed that Xiao’er Fengreqing mixture had antibacterial effects on all six tested bacteria；The MBC experiment results showed that Xiao’er Fengreqing has bactericidal effects on the other five tested bacteria except for Staphylococcus aureus.The CCK-8 results showed that compared with the normal control group，A549 cell viability significantly decreased after Streptococcus pneumoniae infection (P<0.001).Compared with the model group，the degree of cell damage was improved and cell viability increased in the Xiao’er Fengreqing treatment group (P<0.0001，0.01，0.05)；Compared with the normal control group，the levels of NO (P<0.001) and IL-1 β (P<0.001) in the cell supernatant significantly increased after infection with Streptococcus pneumoniae；Compared with the model group，the levels of NO and IL-1β in the cell supernatant of the Xiao’er Fengreqing treatment group decreased.LPS solution inhaled into the lung cavity through the posterior pharynx of mice can cause infiltration of inflammatory cells in the lungs，alveolar hemorrhage and congestion，and consolidation of lung tissue.The total score of pathological evaluation of lung injury is significantly different from that of the control group (P<0.0001)；Compared with the model group，the lung index of mice in the high-dose group of Xiao’er Fengreqing was significantly reduced (P<0.05)；The levels of IL-6，IL-1β，and TNF-α in serum decreased (P<0.01，0.05)；Compared with the model group，the total pathological score of lung injury in mice in the medium dose group of Xiao’er Fengreqing was significantly reduced (P<0.01).In addition，the low，medium，and high dose groups of Xiao’er Fengreqing could significantly improve the degree of lung tissue consolidation in lung injury.Conclusion Xiao’er Fengreqing has a strong inhibitory effect on six common respiratory pathogens，and can significantly improve the cell damage caused by Streptococcus pneumoniae infection in A549 cells，reduce the lung index of LPS induced acute lung injury mice，and improve the pathological morphological abnormalities of lung tissue caused by LPS.This suggests that Xiao’er Fengreqing has therapeutic effects on bacterial endotoxin induced lung injury in mice，and has significant antibacterial and anti-inflammatory abilities.

参考文献/References:

［1］NAGATA Y，YAMAMOTO S，KATO K.Immune checkpoint inhibitors in e-sophageal cancer:clinical development and perspectives［J］.Human vaccines& Immunotherapeutics，2022，18(6)：2143177.
［2］刘宇英，魏君丽，江柔，等.食管癌的流行病学及筛查研究进展［J］.中华疾病控制杂志，2022，26(7)：839-844.
［3］赫捷，陈万青，李兆申，等.中国食管癌筛查与早诊早治指南(2022，北京)［J］.中国肿瘤，2022，31(6)：401-436.
［4］郑玉玲，张亚玲.《中西医结合食管癌治疗方案专家共识》(2021年版)解读［J］.现代中医药，2021，41(6)：11-15.
［5］TSUCHIYA N，KUNISAKI C，SATO S，et al.Chemoradiotherapy for locally advanced esophageal squamous cell carcinoma［J］.Langenbeck，sAr-chives of Surgery，2022，407(5)：1911-1921.
［6］YANG YM，HONG P，XU WW，et al.Advances in targeted therapy for e-sophageal cancer［J］.Signal Transduction and Targeted Therapy，2020，5:229.
［7］韩天赐，刘斌，张亮.食管癌新辅助免疫治疗研究进展［J］.现代肿瘤医学，2024，32(13):2460-2464.
［8］刘前林，周俊东.食管癌放疗联合免疫治疗的研究进展［J］.中国临床新医学，2024，17(5):590-594.
［9］ZHAO B，HUI XD，WANG J，et al.Matrine suppresses lung cancer me-tastasis via targeting M2-like tumour-associated-macrophages polariza-tion［J］.American Journal of Cancer Research，2021，11(9)：4308-4328.
［10］旦增旺姆，韩广素，李晨露，等.中药调节肿瘤免疫微环境发挥抗肿瘤作用研究进展［J］.中西医结合研究，2023，15(6):410-414.
［11］杨迎，侯婷婷，王威，等.黄精多糖的药理作用研究进展［J］.现代 药物与临床，2022，37(3)：659-665.
［12］权利娜，王露，王嘉雯，等.多花黄精总皂苷的提取工 艺及体外抗 氧化研究［J］.现代中医药，2022，42(5)：47-51.
［13］罗婷，罗丹，甘露.黄精多糖的现代药理作用研究进展［J］.临床 合理用药，2023，16(2)：177-180.
［14］边金焕，杜李继，王子丽，等.黄精多糖与积雪草苷对糖尿病斑 马鱼尾鳍再生的药效学研究［J］.中国药学杂志，2023，58(7)：592-598.
［15］龙杰凤，陈文经，李金巧.黄精多糖提取工艺及降糖活性研究［J］.亚太传统医药，2024，2(4):49-53.
［16］李佳纯，刘继业.黄精多糖抗衰老的研究进展［J］.实用老年医学，2024，38(4):334-337.
［17］丛悦，李莉，关佳莉，等.黄精多糖对X射线辐射损伤小鼠外周血象及肠道菌群的影响研究［J］.现代中药研究与实践，2024，38(1):24-29.
［18］XIAO LX，QI L，ZHANG GZ，et al.Polygonatum sibiricum polysaccha-rides attenuate lipopoly-saccharide-induced septic liver injury by suppression of pyroptosis via NLRP3/GSDMD signals［J］.Mole-cules，2022，27(18)：5999.
［19］LIU TY，ZHAO LL，CHEN SB，et al.polygonatum sibiricum polysaccha-rides prevent LpS-induced acute lung injury by inhibiting inflamma-tion via the TLR4/Myd88/NF-KBpathway［J］.Experimental and Therapeutic Medicine，2020，20(4)：3733-3739.
［20］LONG TT，LIU ZJ，SHANG JC，et al.polygonatum sibiricum polysaccha-rides play anti-cancer effect through TLR4-MApK/NF-KBsignaling pathways［J］.International Journal of Biological Macromolecules，2018，111：813-821.
［21］BETANCOURT-CUELLAR SL，BENVENISTE MFK，PALACIO DP，et al.Esopha-geal cancer:tumor-node-metastasis staging［J］.Radiologic clinics of North America，2021，59(2)：219-229.
［22］齐义军，朱亚飞，李恩民.食管癌转移的表观遗传学改变研究进展［J］.食管疾病，2021，3(1):58-63.
［23］PENMAN ID，HENRY E.Advanced esophageal cancer［J］.Gastrointes-tinal Endoscopy clinics of North America，2005，15(1)：101-116.
［24］YAMAMOTO S，KATO K.pembrolizumab for the treatment of esophageal cancer［J］.Expert opinion on Biological Therapy，2020，20(10)：1143-1150.
［25］杨慧超，荀敬，姜晓琳，等.中医药治疗食管癌的作用机制研究进展［J］.中国中西医结合外科杂志，2024，30(3)：419-423.
［26］XU F，SHANGGUAN X，PAN JH，et al.HoXD13 suppresses prostate cancer metastasis and BMp4-induced epithelial-mesenchymal transi-tion by inhibiting SMAD1［J］.International Journal of cancer，2021，148(12)：3060-3070.
［27］何伟，胡勇，佟雅婧.肿瘤免疫抑制及炎性微环境的中 医病机［J］.现代中医药，2022，42(6)：1-5.
［28］柴国静，帖彦清，赵海利.肿瘤相关巨噬细胞对肿瘤转移的影响及靶向治疗的研究进展［J］.中国医药，2024，19(4)：638-640.
［29］LIN YX，XU JX，LAN HY.Tumor-associated macrophages in tumor metastasis:biological roles and clinical therapeutic applications［J］.Journal of Hematology & oncology，2019，12(1)：76.
［30］魏晓环，单前前，朱军.LPS诱导巨噬细胞M1型极化对肿瘤生长的影响［J］.中国现代医生，2024，62(3):54-59.
［31］GENIN M，CLEMENT F，FATTACCIOLI A，et al.M1 and M2 macrophages derived from THp-1 cells differentially modulate the response of cancer cells toetoposide［J］.BMc cancer，2015，15:577.
［32］BHAT AA，NISAR S，MAACHA S，et al.cytokine-chemokine network driven metastasis in esophageal cancer;promising avenue for targe-ted therapy［J］.Molecular cancer，2021，20(1)：2.
［33］陈吉豪，唐佳佳，陈晓钢，等.LGR4通过调控上皮-间充质转化促进宫颈癌转移［J］.中国细胞生物学学报，2022，44(3):413-420.
［34］卢洪胜，於樱枝，牟樱红，等.FOXK1通过上皮间充质转化促进胃癌浸润转移研究［J］.现代实用医学，2018，30(4):436-438，416.
［35］HUANG RL，WANG SQ，WANG N，et al.ccL5 derived from tumor-asso-ciated macrophages promotes prostate cancer stem cells and metasta-sis via activating β-catenin/STAT3 signaling［J］.cell Death & Dis-ease，2020，11(4)：234.
［36］YANG C，DOU R，XIONG B，et al.Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis［J］.Mol Ther，2021，29(6):2088-2107.
［37］BOUTILIER AJ，ELSAWA SF.Macrophage polarization states in the tumor microenvironment［J］.International Journal of Molecular Sciences，2021，22(13)：6995.
［38］YU T，GAN SC，ZHU QC，et al.Modulation of M2 macrophage polari-zation by the crosstalk between Stat6 and Trim24［J］.Nature com-munications，2019，10:4353.
［39］HUANG CY，WANG J，LIU HB，et al.Ketone body β-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway［J］.BMc Medicine，2022，20(1)：148.
［40］QUERO L，HALL J，KYBURZ D，et al.miR-221-3p Drives the Shift of M2-Macrophages to a Pro-Inflammatory Function by Suppressing JAK3/STAT3 Activation［J］.Front Immunol，2020，10:3087.

备注/Memo

备注/Memo:
基金项目：河北省重点研发计划项目（22372501D）；河北省中医药管理局科研计划项目（2022318，2022319）;邯郸市科学技术研究与发展计划项目（22313014001；23313014008）；邯郸市科学技术研究与发展计划项目（21112093033）；
更新日期/Last Update: 2024-09-20